Commentary · 1 Jul 2026
Conference abstractPublished 19 Nov 2012
1'-Acetoxychavicol acetate inhibits growth of human oral carcinoma xenograft in mice and potentiates cisplatin effect via proinflammatory microenvironment alterations
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Oral cancers although preventable, possess a low five-year survival rate which has remained unchanged over the past three decades. In an attempt to find a more safe, affordable and effective treatment option, we describe here the use of 1?S-1?- acetoxychavicol acetate (ACA), a component of the Malaysian ginger traditionally used for various medicinal purposes. Whether ACA can inhibit the growth of oral squamous cell carcinoma (SCC) cells alone or in combination with cisplatin (CDDP), was explored both in vitro and in vivo using Nu/Nu mice. Occurrence of apoptosis was assessed using PARP and DNA fragmentation assays, while the mode of action was elucidated through global expression profiling followed by Western blotting and IHC assays. We found that ACA alone inhibited the growth of oral SCC cells, induced apoptosis and suppressed its migration rate, while minimally affecting HMEC normal cell controls. ACA further enhanced the cytotoxic effects of CDDP in a synergistic manner as suggested by combination index studies, and inhibited the constitutive activation of NF-κB through suppression of IKKα/β activation. Human oral tumor xenografts studies in mice revealed that ACA alone was as effective as CDDP in reducing tumor volume, and further potentiated CDDP effects when used in combination, with reduced body weight loss. The effects of ACA also correlated with a down-regulation of NF-κB regulated genes (FasL and Bim), including proinflammatory (NF-κB and COX- 2) and proliferative (cyclin D1) biomarkers in tumor tissue. Overall, our results suggest that ACA inhibits the growth of oral SCC and further potentiates the effect of standard CDDP treatment by modulation of the proinflammatory microenvironment. Current preclinical data forms the basis for further clinical trials to improve the current standards for oral cancer care.
Subjects
Genetics & Molecular BiologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
More from this journal
The newest in Journal of Genetic Syndromes & Gene Therapy.
Perspective · 1 Jul 2026
Lentiviral Gene Integration Systems in Hematologic Genetic Blood Disorders
Perspective · 1 Jul 2026
Programmable RNA Editing Systems in Congenital Skeletal Dysplasia Disorders
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Genetic Syndromes & Gene Therapy
- SubjectGenetics & Molecular Biology
- BylineArticles whose byline prints “Noor Hasima Nagoor”
